Fig. 1

FDA approval timeline of INSTI single and fixed dose combination products used for HIV-1 treatment and prevention *discontinued, 3TC lamivudine, ABC abacavir, COBI cobicistat, FTC emtricitabine, HD high dose, RPV rilpivirine, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate